The present invention relates to TP receptor antagonists, which have the ability to bind to TP receptor and optionally cross the blood brain barrier. The invention also provides compositions and methods for treating a disorder wherein activation of TP receptor is detrimental.
Novel Tetrahydronaphalene Antagonists to the Thromboxane A2 (TP) Receptor